CMTX-101 Study is testing a new treatment for bacterial pneumonia, which is a lung infection. It uses a special protein called a monoclonal antibody to help antibiotics work better. This study aims to ensure the treatment is safe for people. First, healthy volunteers will participate, followed by patients with moderate community-acquired bacterial pneumonia (CABP).

Participants will receive a one-time intravenous (IV) dose of CMTX-101, which means the medicine is delivered directly into a vein over an hour. Healthy volunteers must be 18 or older and in good health. Those with pneumonia must have certain symptoms like fever or trouble breathing.

Participants cannot join if they have certain health problems, are pregnant, or are taking part in another study. The study helps researchers learn if the treatment is safe and how the body processes it.

• Single IV infusion lasts about 60 minutes.
• Participants must follow birth control guidelines.
• Screening includes health checks and pregnancy tests for women.